Sign in
Taking peoplePhase 2

Proof-of-Concept Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of Intranasal Cenegermin in Adult Participants with moderate to severe Traumatic Brain Injury (TBI).

Key facts

Who runs it
Dompe' Farmaceutici S.p.A.
Where
Denmark, Finland, France, Germany, Italy, Poland, Spain, and Sweden26 sites in 8 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 2
People taking part
146 people, planned
Started
13 Jul 2026
Expected to end
31 May 2028
Type of study
Interventional
Record updated
10 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Male and female adults 18 to 70 years of age
  • TBI resulting in hospital evaluation within the last 2-8 weeks prior to informed consent
  • A clinical diagnosis of moderate to severe TBI (defined by Glasgow Coma Scale [GCS] score 3 to 12), considering the highest GCS score assessed within 24 hours following injury
  • Confirmed TBI diagnosis by computed tomography (CT) assessed by the investigator
  • Anticipated discharge to a rehabilitation setting within a facility or at home

Who cannot take part

  • Pre-existing medical conditions which can continue to produce functional disability up to the time of injury
  • GOS-E score of 7 (lower good recovery) or 8 (upper good recovery) at time of informed consent
  • Penetrating TBI (eg, gunshot, stabs)
  • Medically refractory brain edema at time of screening
  • Dependence on invasive mechanical ventilation without the ability to sustain spontaneous breathing at time of screening
  • Poor survival prognosis (investigator assessment)

This trial has no sites in United States.

It has sites in 8 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the safety and tolerability of intranasal cenegermin in participants with moderate to severe subacute TBI.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group, Adaptive Proof-of-concept, Dose-selecting Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intranasal Cenegermin (recombinant human Nerve Growth Factor [rhNGF]) in Adult Participants with subacute moderate to severe Traumatic Brain Injury (TBI).
Record updated
10 September 2026